Previous 10 | Next 10 |
NEW YORK, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that an analyst note commenting on the...
After seeing that Ocaliva is no longer cited in FDA’s updated NISS webpage for Q3 2020, RBC Capital Markets believes the regulator has completed the evaluation of the FAERS signal of the only commercialized therapy of Intercept Pharmaceuticals (ICPT).With analysts Brian Abrahams and th...
Bank of America Securities downgrades Intercept Pharmaceuticals (ICPT) to Underperform from Neutral expecting the rising competition on the company’s target markets to potentially lower its long-term prospects.The analysts have lowered Intercept’s price target to $27 from $40, a...
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Jared M. Freedberg ...
Noting that biotech valuations are attractive vs. the broader market, Oppenheimer delves into the sector to uncover the trends that will continue in 2021.Comparing the absolute valuations of the Nasdaq Biotechnology Index (NBI) and the S&P 500, the analysts led by Jay Olson observe the ...
Intercept has suffered an important set back with the FDA’s CRL for Ocaliva in NASH with liver fibrosis. Ocaliva may still be approvable in NASH and the risk-reward for ICPT is more appealing at current levels. Ocaliva is approved in PBC and quarterly sales are growing 30% ...
NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief ...
LPCN’s long road to market for its oral testosterone pill has been bumpy; however, the FDA just gave TLANDO tentative approval. LPCN traded down on the approval, but traders are missing out on the bigger picture: the company's promising drug candidate in NASH, and a market with...
Intercept Pharmaceuticals (ICPT) -6.9% PM, promoted current COO Jerome (Jerry) Durso to the president & CEO position, effective Jan.1, 2021, succeeding Mark Pruzanski.He will also be appointed to the board post the transition.Jerry has been serving as COO since February 2017; most re...
Jerry Durso Appointed CEO Effective January 1, 2021 ; Founder, President and CEO Mark Pruzansk i to Continue as Board Member and Advis o r NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (N...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...